Insider Selling: Exact Sciences Co. (NASDAQ:EXAS) CFO Sells 2,710 Shares of Stock

Exact Sciences Co. (NASDAQ:EXASGet Free Report) CFO Jeffrey Thomas Elliott sold 2,710 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $56.89, for a total transaction of $154,171.90. Following the sale, the chief financial officer now directly owns 8,054 shares in the company, valued at $458,192.06. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jeffrey Thomas Elliott also recently made the following trade(s):

  • On Wednesday, February 21st, Jeffrey Thomas Elliott sold 1,493 shares of Exact Sciences stock. The stock was sold at an average price of $61.50, for a total transaction of $91,819.50.
  • On Thursday, February 15th, Jeffrey Thomas Elliott sold 1,888 shares of Exact Sciences stock. The shares were sold at an average price of $61.43, for a total value of $115,979.84.

Exact Sciences Stock Performance

NASDAQ EXAS traded down $0.59 on Wednesday, reaching $56.31. The stock had a trading volume of 1,628,300 shares, compared to its average volume of 1,976,769. The stock has a market cap of $10.22 billion, a P/E ratio of -49.39 and a beta of 1.27. Exact Sciences Co. has a 12-month low of $56.05 and a 12-month high of $100.77. The business’s 50-day moving average price is $65.93 and its 200 day moving average price is $68.45. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.07 and a current ratio of 2.32.

Exact Sciences (NASDAQ:EXASGet Free Report) last released its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.26. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The firm had revenue of $646.89 million during the quarter, compared to the consensus estimate of $638.83 million. During the same quarter in the prior year, the firm earned ($0.72) EPS. Exact Sciences’s revenue for the quarter was up 17.0% on a year-over-year basis. As a group, equities analysts expect that Exact Sciences Co. will post -0.95 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on EXAS shares. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 22nd. TheStreet downgraded shares of Exact Sciences from a “c-” rating to a “d+” rating in a research note on Monday. Canaccord Genuity Group reduced their price objective on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. Guggenheim assumed coverage on shares of Exact Sciences in a research report on Thursday, December 14th. They set a “buy” rating and a $90.00 price objective for the company. Finally, The Goldman Sachs Group dropped their target price on Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, November 3rd. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $99.31.

Get Our Latest Stock Report on Exact Sciences

Hedge Funds Weigh In On Exact Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. True Wealth Design LLC acquired a new stake in Exact Sciences during the 4th quarter worth approximately $30,000. Wolff Wiese Magana LLC raised its stake in shares of Exact Sciences by 459.5% during the fourth quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock worth $31,000 after purchasing an additional 340 shares during the last quarter. KB Financial Partners LLC acquired a new stake in shares of Exact Sciences during the second quarter worth $32,000. BluePath Capital Management LLC purchased a new position in Exact Sciences in the 3rd quarter valued at $33,000. Finally, Newbridge Financial Services Group Inc. purchased a new position in Exact Sciences in the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 89.13% of the company’s stock.

Exact Sciences Company Profile

(Get Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Featured Stories

Insider Buying and Selling by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.